Clinical practice of renal cell carcinoma treatment with nivolumab

被引：0
|
作者：
Potocki, Pawel M. [1 ]
Wysocki, Piotr J. [1 ]
机构：
[1] Jagiellonian Univ, Coll Med, Dept Oncol, Krakow, Poland
来源：
ONCOLOGY IN CLINICAL PRACTICE | 2019年 / 15卷 / 05期
关键词：
kidney cancer; renal cell carcinoma; nivolumab; anti-PD-1; immunotherapy; checkpoint inhibitor; RANDOMIZED PHASE-3; CHECKMATE; 025; CANCER; EVEROLIMUS; IMMUNITY; SUNITINIB; BLOCKADE; EFFICACY; THERAPY; SAFETY;
D O I：
10.5603/OCP.2019.0002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Nivolumab alike other immune checkpoint inhibitors has been intensively developed during the last decade. Kidney cancer is among the neoplasm in treatment of which we have accumulated the most experience regarding nivolumab. As improves our understanding of the mechanisms underlying specific cellular immune response, thus improves our understanding of the place the nivolumab holds among other therapeutic options. Recent years brought development of innovative immunotherapy combinations as a method for improving immunotherapy efficacy. This review aims at providing practicing oncologists with key aspects of renal cell carcinoma treatment with nivolumab.
引用
收藏
页码：237 / 245
页数：9
相关论文
共 50 条
  • [1] Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice
    Joseph, Richard W.
    Chatta, Gurkamal
    Vaishampayan, Ulka
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (04) : 142 - 148
  • [2] Nivolumab in the treatment of advanced renal cell carcinoma
    Arasaratnam, Malmaruha
    Gurney, Howard
    [J]. FUTURE ONCOLOGY, 2018, 14 (17) : 1679 - 1689
  • [3] Nivolumab in the treatment of advanced renal cell carcinoma
    Tomczak, Piotr
    Synowiec, Zuzanna
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2019, 15 (02): : 124 - 126
  • [4] Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma
    Farolfi, Alberto
    Schepisi, Giuseppe
    Conteduca, Vincenza
    Burgio, Salvatore Luca
    Lolli, Cristian
    De Giorgi, Ugo
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (09) : 1089 - 1096
  • [5] Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience
    Mennitto, Alessia
    Grassi, Paolo
    Ratta, Raffaele
    Verzoni, Elena
    Prisciandaro, Michele
    Procopio, Giuseppe
    [J]. THERAPEUTIC ADVANCES IN UROLOGY, 2016, 8 (05) : 319 - 326
  • [6] Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Powles, T.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 (03) : 422 - 423
  • [7] An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma
    Zarrabi, Kevin
    Wu, Shenhong
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (06) : 695 - 705
  • [8] Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma
    Gao, Xin
    McDermott, David F.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (09) : 947 - 957
  • [9] Immunotherapy with nivolumab in metastatic renal cell carcinoma patients in India: Bringing a change in clinical practice
    Rauthan, A.
    Patil, P.
    Prasannakumar, S. Sampige
    Zaveri, S.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [10] Nivolumab in treatment of renal cell carcinoma during renal replacement therapy
    Konopka, Kamil
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2019, 15 (01): : 75 - 77
12345